Back

Development and validation of a novel bleeding risk score during direct oral anticoagulant therapy in patients with cancer-associated venous thromboembolism

29 August 2026 (11:15 - 11:45)
Organised by: Logo
Congress Presentation Part of: Managing and improving safety in antithrombotic pharmacotherapy Anticoagulants ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Tomoyuki Nagai

Kyoto Prefectural University of Medicine, Kyoto (Japan)

3 More presentations in this session

Presentation thumbnail
Oral anticoagulation monotherapy versus dual antithrombotic therapy in chronic coronary syndrome patients requiring long-term anticoagulation: a bayesian meta-analysis of randomised controlled trials
Doctor B. Rodriguez-Tapia (Trujillo, PE)
Abstract Slides
Presentation thumbnail
Intraoperative antithrombotic drug removal during urgent CABG: early German experience with a novel hemoadsorption device
Professor U. Zeymer (Ludwigshafen, DE)
Abstract Slides
Presentation thumbnail
Outcomes of reduced-dose versus standard-dose apixaban in atrial fibrillation patients meeting dose-reduction criteria: a propensity score–matched analysis
Doctor A. Ajibade (Iowa City, US)
Abstract Slides

Access the full session

Session thumbnail
Managing and improving safety in antithrombotic pharmacotherapy

The Event

Event poster

ESC Congress 2026

29 August 2026 11:15 CET
You may be interested in
thumbnail
Congress Presentation
Prediction of major bleeding in patients receiving DOACs for venous thromboembolism: a prospective cohort study.
31 August 2019
thumbnail
Webinar
Anticoagulation issues in cancer patients
26 April 2021
thumbnail
Congress Presentation
Validation of the European SCORE2 algorithm in four European and non-European cohort studies with contrasting populations
3 April 2025
thumbnail
Congress Presentation
Paraneoplastic venous thromboembolism: a key to early cancer detection and risk management
20 June 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources